Non Viral DNA & RNA Therapeutics
Through the core
We are a clinical-stage Synthetic Biology company developing non viral DNA and RNA-based vaccines and gene therapies for critical medical needs in humans and animals.
Non Viral DNA & RNA Therapeutics
Through the core.
We are a clinical-stage Synthetic Biology company developing non viral DNA and RNA-based vaccines and gene therapies for critical medical needs in humans and animals.
Discover the future of medicine
Our Technology
Nucleic acids encode the essential instructions governing biological processes, determining health, adaptation, and disease. At SYTE.bio, we harness this intrinsic power through DNA and RNA technologies to develop advanced therapeutics and vaccines. Our platforms enable patients’ tissues to autonomously generate therapeutic agents, targeting the genetic origins of disease or amplifying natural biological functions. By directly modifying these molecular blueprints, SYTE.bio pioneers precise, scalable solutions—from eradicating chronic conditions to engineering adaptable vaccines for humans and animals. Rooted in the transformative potential of genetic innovation, we redefine Synthetic Biology horizons through visionary science that prioritizes real-world impact.
Human Health
Vaccines
We pioneer adaptive vaccine design using DNA and RNA platforms to express single or multi-antigen profiles that can be combined with immune-enhancing adjuvants. DNA vaccines establish enduring immune memory, while RNA rapidly delivers antigens for emerging threats. This synergy ensures versatility for rapid deployment and cross-platform compatibility.
Therapies
Our DNA and RNA platforms empower precision medicine by tailoring expression timelines to disease demands: long-term solutions for chronic conditions like diabetes and ostheoarthritis, mid-term therapies for pain management, and oncology, and short-term interventions for acute issues such as dermatitis. DNA-based systems drive durable gene expression, while RNA technologies enable transient, targeted pathway modulation.
Animal Health
Vaccines
Harnessing our DNA and RNA platforms, we engineer vaccines targeting multi-pathogen threats like parasites, viruses and other microorganisms with integrated immune boosters. DNA ensures robust, long-lasting livestock and companion animals protection, while RNA enables agile responses to zoonotic outbreaks. Both platforms emphasize cost-efficiency, species-specific efficacy, and our commitment to safeguarding animal populations against evolving biological risks.
Therapies
Our DNA and RNA platforms deliver species-specific therapies calibrated to animal health needs: long-term genetic expression to address inherited disorders (e.g., metabolic dysfunctions), mid-term modulation for degenerative conditions, and short-term interventions for transient gene-related conditions. DNA-based therapies correct or replace faulty genes for lifelong solutions, while RNA technologies temporarily regulate aberrant pathways in age-related or acquired genetic diseases.
Animal health pipeline for oncology
DISEASE & PRODUCT
RESEARCH
OPTIMIZATION
PRE-CLINICAL
PHASE I
PHASE II
PHASE III
MARKET LAUNCH
INVIVO-mAb Anti CTLA4
Melanoma
Sarcoma
Squamous Cell Carcinoma
Transitional Cell Carcinoma
IL-12
GM-CSF
INVIVO-mAb Anti PDL-1
INVIVO-mAb Bi-Specific
ABOUT US
SYTE.bio
As a leading clinical-stage synthetic biology company, our main goal is to combine unique human talent with cutting-edge technology to develop better, safer, and more effective therapeutics, enhancing quality of life and longevity for millions of humans and animals.
